ArticlePsychopharmacology2015
Effect of extended-release naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin-dependent patients.
Article in Psychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- A systematic review of the potential effects of medications and drugs of abuse on dopamine transporter imaging using [European journal of nuclear medicine and molecular imaging · 2023Pooled it
- Effects of sedative drug use on the dopamine system: a systematic review and meta-analysis of in vivo neuroimaging studies.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019Pooled it
- Acupuncture plus wet cupping therapy for post stroke depression: a randomized controlled trial.Frontiers in psychiatry · 2026Trial
- Suicidal ideation in adults with opioid use disorder treated with buprenorphine-naloxone versus extended-release naltrexone.The American journal of drug and alcohol abuse · 2025Trial
- Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up Study.JAMA psychiatry · 2019Trial
- Amomum tsao-ko crevost et lemaire ameliorates depression-like behaviors and hippocampal inflammation by inhibiting microglia activation and HMGB1/TLR4/NF-κB pathway in diabetic mice with depression.Metabolic brain disease · 2025Article
- Ginsenoside Rg1: A Neuroprotective Natural Dammarane-Type Triterpenoid Saponin With Anti-Depressive Properties.CNS neuroscience & therapeutics · 2024Review
- Review
- Neuroimaging Techniques in Differentiating Parkinson's Disease from Drug-Induced Parkinsonism: A Comprehensive Review.Clinics and practice · 2023Review
- Ferulic acid as a therapeutic agent in depression: Evidence from preclinical studies.CNS neuroscience & therapeutics · 2023Review
- Depressive Symptomatology Is Associated With Smaller Reductions in Drug Cue Reactivity During Extended-Release Naltrexone Treatment of Opioid Use Disorder.The Journal of clinical psychiatry · 2023Article
- Article
- Sex differences in cognitive function among Chinese older adults using data from the Chinese longitudinal healthy longevity survey: a cross-sectional study.Frontiers in public health · 2023Article
- Mediation of the behavioral effects of ketamine and (2R,6R)-hydroxynorketamine in mice by kappa opioid receptors.Psychopharmacology · 2022Article
- Suicide Risk and Addiction: The Impact of Alcohol and Opioid Use Disorders.Current addiction reports · 2021Review
- Anhedonia as a key clinical feature in the maintenance and treatment of opioid use disorder.Clinical psychological science : a journal of the Association for Psychological Science · 2019Article
- Addiction, Anhedonia, and Comorbid Mood Disorder. A Narrative Review.Frontiers in psychiatry · 2019Review
- Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders.Frontiers in psychiatry · 2019Review
- Clinical evaluation of [EJNMMI research · 2018Article
- Antagonists in the medical management of opioid use disorders: Historical and existing treatment strategies.The American journal on addictions · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleExtended-release naltrexone (XRNT), an opioid receptor antagonist, is successfully used in the treatment of opioid dependence. However, naltrexone treatment of opioid-dependent patients may reduce striatal dopamine transporter (DAT) availability and cause depression and anhedonia.
objectivesThe aim of this study is to investigate changes in striatal DAT availability and symptoms of depression (Beck Depression Inventory (BDI)) and anhedonia (Snaith Hamilton Pleasure Scale (SHAPS)) before and during XRNT treatment.
methodsAt baseline, ten detoxified heroin-dependent patients and 11 matched healthy controls underwent [(123)I]FP-CIT single photon emission computed tomography (SPECT) imaging to assess striatal DAT binding. Patients underwent a second SPECT scan 2 weeks after an intramuscular injection with XRNT.
resultsAt baseline, the mean binding potential (BPND) in the putamen was at a trend level lower and the mean BDI score was significantly higher in heroin patients (n = 10) than in controls (n = 11) (3.45 ± 0.88 vs. 3.80 ± 0.61, p = 0.067, d = -0.48 and 12.75 ± 7.40 vs. 5.20 ± 4.83, p = 0.019, d = 1.24, respectively). Post hoc analyses in subgroups with negative urine analyses for opioids and cocaine showed significantly lower baseline putamen BPND in heroin patients (n = 8) than controls (n = 10) (3.19 ± 0.43 vs. 3.80 ± 0.64, p = 0.049, d = -1.03). XRNT treatment in heroin patients was not significantly associated with changes in striatal DAT availability (p = 0.348, d = 0.48), but the mean BDI score after XRNT treatment was significantly lower than before treatment (7.75 ± 7.21 vs. 12.75 ± 7.40, p = 0.004, d = -0.68).
conclusionsThe results of this study suggest that XRNT treatment does not reduce striatal DAT availability and has no significant effect on anhedonia, but is associated with a significant reduction of depressive symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.